Cracking “Undruggable” Cancer Proteins: Precision Oncology Meets p53
The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic...
Progress Against Cancer
The development of KRAS inhibitors has ushered in a new era in precision oncology and renewed efforts in therapeutic...
At the AACR-Industry Roundtable 2026 representatives from academia, patient advocacy, the biopharmaceutical industry, and federal agencies came together to...
The recent AACR Grantee Summit showcased the impactful research funded by AACR grants, including new targeted therapy approaches, miniaturized...
In the latest edition of From the Bench, the AACR Blog explores recent innovative approaches to cancer research, including...
The October 2026 Editors’ Picks from AACR journals include findings on multiple primary cancers in World Trade Center responders,...
Results from a phase III trial showed that a cancer vaccine can improve outcomes for certain patients with melanoma,...
At the recent AACR Conference on Pancreatic Cancer, researchers explored the complex interactions among tumor cells, neurons, and the...
